Published in Antimicrob Agents Chemother on July 30, 2007
Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. Antimicrob Agents Chemother (2008) 0.90
Therapeutic aerosol bioengineering of targeted, inhalable microparticle formulations to treat Mycobacterium tuberculosis (MTb). J Mater Sci Mater Med (2011) 0.80
An isoniazid analogue promotes Mycobacterium tuberculosis-nanoparticle interactions and enhances bacterial killing by macrophages. Antimicrob Agents Chemother (2012) 0.78
Macrophage apoptosis in response to high intracellular burden of Mycobacterium tuberculosis is mediated by a novel caspase-independent pathway. J Immunol (2006) 2.22
THP-1 cell apoptosis in response to Mycobacterial infection. Infect Immun (2003) 1.77
Role of phagocytosis in the activation of macrophages. J Exp Med (1978) 1.77
Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm Res (2000) 1.56
Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur J Pharm Sci (2007) 1.39
Mycobacterial manipulation of the host cell. FEMS Microbiol Rev (2005) 1.37
Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm Res (2001) 1.31
Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrob Chemother (2005) 1.11
Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm Res (2001) 1.10
Enhancement of antimycobacterial activity of macrophages by stabilization of inner mitochondrial membrane potential. J Infect Dis (2005) 1.09
Proapoptotic activity of Caenorhabditis elegans CED-4 protein in Drosophila: implicated mechanisms for caspase activation. Proc Natl Acad Sci U S A (1999) 1.08
In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres. Eur J Pharm Sci (2002) 1.01
P2X receptor characterization and IL-1/IL-1Ra release from human endothelial cells. Br J Pharmacol (2007) 0.99
High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection. Antimicrob Agents Chemother (1999) 0.98
Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra. J Antimicrob Chemother (2007) 0.98
A correlation between phagocytosis and apoptosis in THP-1 cells infected with prevalent strains of Mycobacterium tuberculosis. Microbiol Immunol (2007) 0.81
Failure of a prothionamide-containing oral antituberculosis regimen. S Afr Med J (1985) 0.81
Discovery-based science education: functional genomic dissection in Drosophila by undergraduate researchers. PLoS Biol (2005) 2.33
Design of radiation tolerant materials via interface engineering. Adv Mater (2013) 1.47
Genomewide clonal analysis of lethal mutations in the Drosophila melanogaster eye: comparison of the X chromosome and autosomes. Genetics (2007) 1.44
Smallest metallic nanorods using physical vapor deposition. Phys Rev Lett (2013) 1.42
Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur J Pharm Sci (2007) 1.39
Spiral patterns of dislocations at nodes in (111) semi-coherent FCC interfaces. Sci Rep (2013) 1.19
Open source drug discovery--a new paradigm of collaborative research in tuberculosis drug development. Tuberculosis (Edinb) (2011) 1.11
Emergence of stable interfaces under extreme plastic deformation. Proc Natl Acad Sci U S A (2014) 1.02
Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra. J Antimicrob Chemother (2007) 0.98
Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. Antimicrob Agents Chemother (2008) 0.90
A hand-held apparatus for "nose-only" exposure of mice to inhalable microparticles as a dry powder inhalation targeting lung and airway macrophages. Eur J Pharm Sci (2008) 0.89
Controlling heterojunction abruptness in VLS-grown semiconductor nanowires via in situ catalyst alloying. Nano Lett (2011) 0.84
Aerosol vaccines for tuberculosis: a fine line between protection and pathology. Tuberculosis (Edinb) (2010) 0.83
Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice. Antimicrob Agents Chemother (2012) 0.82
Loading and release of amphotericin-B from biodegradable poly(lactic-co-glycolic acid) nanoparticles. J Biomed Nanotechnol (2011) 0.82
Inhalable microparticles of nitric oxide donors induce phagosome maturation and kill Mycobacterium tuberculosis. Tuberculosis (Edinb) (2013) 0.81
Inhalable microparticles containing nitric oxide donors: saying NO to intracellular Mycobacterium tuberculosis. Mol Pharm (2012) 0.80
Partial biodistribution and pharmacokinetics of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to rhesus macaques. Mol Pharm (2012) 0.79
Inhalable particles containing rapamycin for induction of autophagy in macrophages infected with Mycobacterium tuberculosis. Mol Pharm (2014) 0.79
Inhalable microparticles containing isoniazid and rifabutin target macrophages and 'stimulate the phagocyte' to achieve high efficacy. Indian J Exp Biol (2009) 0.79
Nanoparticles containing nitric oxide donor with antileishmanial agent for synergistic effect against visceral leishmaniasis. J Biomed Nanotechnol (2011) 0.78
Microparticles induce variable levels of activation in macrophages infected with Mycobacterium tuberculosis. Tuberculosis (Edinb) (2010) 0.78
HLA-DRB1*1501 and VDR polymorphisms and survival of Mycobacterium tuberculosis in human macrophages exposed to inhalable microparticles. Pharmacogenomics (2013) 0.78
Inhaled therapies for tuberculosis and the relevance of activation of lung macrophages by particulate drug-delivery systems. Ther Deliv (2011) 0.78
Inhalable microparticles modify cytokine secretion by lung macrophages of infected mice. Tuberculosis (Edinb) (2010) 0.78
Osteogenic efficacy enhancement of kaempferol through an engineered layer-by-layer matrix: a study in ovariectomized rats. Nanomedicine (Lond) (2013) 0.77
Particulate pulmonary delivery systems containing anti-tuberculosis agents. Crit Rev Ther Drug Carrier Syst (2013) 0.77
Optimisation of inhaled tuberculosis therapies and implications for host-pathogen interactions. Tuberculosis (Edinb) (2010) 0.77
Dry powder antibiotic aerosol product development: inhaled therapy for tuberculosis. J Pharm Sci (2013) 0.76
Nanoscaffold matrices for size-controlled, pulsatile transdermal testosterone delivery: nanosize effects on the time dimension. Nanotechnology (2008) 0.75
When history really is not applicable or relevant. Arch Intern Med (2009) 0.75
Fluid and Resistive Tethered Lipid Membranes on Nanoporous Substrates. J Phys Chem B (2015) 0.75
Biodegradable nanoparticles in the murine vagina: trans-cervical retrograde transport and induction of proinflammatory cytokines. J Biomed Nanotechnol (2011) 0.75
Preparation of tetanus toxoid and ovalbumin loaded gliadin nanoparticles for oral immunization. J Biomed Nanotechnol (2011) 0.75
Direct observations of confined layer slip in Cu/Nb multilayers. Microsc Microanal (2012) 0.75
Episodic transdermal delivery of testosterone. Mol Pharm (2012) 0.75
The devil's advocacy: when and why inhaled therapies for tuberculosis may not work. Tuberculosis (Edinb) (2010) 0.75
A single-tilt TEM stereomicroscopy technique for crystalline materials. Microsc Microanal (2003) 0.75
349: USE OF SYSTOLIC CAROTID FLOW IN PREDICTING VOLUME RESPONSIVENESS. Crit Care Med (2016) 0.75
Single nucleotide polymorphic macrophage cytokine regulation by Mycobacterium tuberculosis and drug treatment. Pharmacogenomics (2014) 0.75